Biogen Senses 'Interesting Opportunities' If Financial Markets Remain Challenging
This article was originally published in The Pink Sheet Daily
Firm earmarks $100m for business development in 2016, and says the market appears to be turning in favor of buyers.
You may also be interested in...
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
The US FDA appears to have concerns about the device used to administer the vaccine.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.